BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang SS, Liu W, Ly D, Xu H, Qu L, Zhang L. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol 2019;16:6-18. [PMID: 29628498 DOI: 10.1038/s41423-018-0027-x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 152] [Article Influence: 17.3] [Reference Citation Analysis]
Number Citing Articles
1 Lu L, Zheng D, Qu J, Zhuang Y, Peng J, Lan S, Zhang S, Huang F. METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma. Front Cell Dev Biol 2022;10:759020. [DOI: 10.3389/fcell.2022.759020] [Reference Citation Analysis]
2 Takahashi K, Kurashina K, Yamaguchi H, Kanamaru R, Ohzawa H, Miyato H, Saito S, Hosoya Y, Lefor AK, Sata N, Kitayama J. Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer. Front Immunol 2022;13:969468. [DOI: 10.3389/fimmu.2022.969468] [Reference Citation Analysis]
3 Qu R, Ye F, Hu S, Wang B, Qin S, Xiong J, Fu X, Li L, Cai Y. Distinct cellular immune profiles in lung adenocarcinoma manifesting as pure ground glass opacity versus solid nodules. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04289-3] [Reference Citation Analysis]
4 Eismann L, Rodler S, Buchner A, Schulz GB, Volz Y, Bischoff R, Ebner B, Westhofen T, Casuscelli J, Waidelich R, Stief C, Schlenker B, Ledderose S. Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder. Cancers 2022;14:3999. [DOI: 10.3390/cancers14163999] [Reference Citation Analysis]
5 Yin X, Liao H, Yun H, Lin N, Li S, Xiang Y, Ma X. Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer. Semin Cancer Biol 2022:S1044-579X(22)00182-1. [PMID: 35963564 DOI: 10.1016/j.semcancer.2022.08.002] [Reference Citation Analysis]
6 Zhu J, Weng Y, Wang F, Zhao J. LINC00665/miRNAs axis-mediated collagen type XI alpha 1 correlates with immune infiltration and malignant phenotypes in lung adenocarcinoma. Open Med (Wars) 2022;17:1259-74. [PMID: 35892083 DOI: 10.1515/med-2022-0478] [Reference Citation Analysis]
7 Zhao Y, Zhang Q, Tu K, Chen Y, Peng Y, Ni Y, Zhu G, Cheng C, Li Y, Xiao X, Yu C, Lu K, Chen Y, Li C, Tang J, Wang G, Luo W, Zhang W, Che G, Li W, Wang Z, Xie D. Single-Cell Transcriptomics of Immune Cells Reveal Diversity and Exhaustion Signatures in Non-Small-Cell Lung Cancer. Front Immunol 2022;13:854724. [PMID: 35874785 DOI: 10.3389/fimmu.2022.854724] [Reference Citation Analysis]
8 Lin Y, Zhou H, Li S. BTN3A2 Expression Is Connected With Favorable Prognosis and High Infiltrating Immune in Lung Adenocarcinoma. Front Genet 2022;13:848476. [PMID: 35873496 DOI: 10.3389/fgene.2022.848476] [Reference Citation Analysis]
9 Ullah MA, Islam NN, Moin AT, Park SH, Kim B. Evaluating the Prognostic and Therapeutic Potentials of the Proteasome 26S Subunit, ATPase (PSMC) Family of Genes in Lung Adenocarcinoma: A Database Mining Approach. Front Genet 2022;13:935286. [DOI: 10.3389/fgene.2022.935286] [Reference Citation Analysis]
10 Su Z, Shu K, Li G. Increased ANXA5 expression in stomach adenocarcinoma infers a poor prognosis and high level of immune infiltration. CBM 2022. [DOI: 10.3233/cbm-210482] [Reference Citation Analysis]
11 Liu W, Powell CA, Wang Q. Tumor microenvironment in lung cancer-derived brain metastasis. Chin Med J (Engl) 2022. [PMID: 35838548 DOI: 10.1097/CM9.0000000000002127] [Reference Citation Analysis]
12 Li Q, Zhang P, Hu H, Huang H, Pan D, Mao G, Hu B. The DDR-related gene signature with cell cycle checkpoint function predicts prognosis, immune activity, and chemoradiotherapy response in lung adenocarcinoma. Respir Res 2022;23:190. [PMID: 35840978 DOI: 10.1186/s12931-022-02110-w] [Reference Citation Analysis]
13 Tian W, Zhou J, Chen M, Qiu L, Li Y, Zhang W, Guo R, Lei N, Chang L. Bioinformatics analysis of the role of aldolase A in tumor prognosis and immunity. Sci Rep 2022;12:11632. [PMID: 35804089 DOI: 10.1038/s41598-022-15866-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Wu X, Wang Y, Chen C, Xue Y, Zheng S, Cai L, Khawar MB. Hsa-let-7c-5p, hsa-miR-130b-3p, and hsa-miR-142-3p as Novel miRNA Biomarkers for Melanoma Progression. Genetics Research 2022;2022:1-12. [DOI: 10.1155/2022/5671562] [Reference Citation Analysis]
15 Zhang Y, Yue Q, Cao F, Li Y, Wei Y. Necroptosis-related lncRNA signatures determine prognosis in breast cancer patients. Sci Rep 2022;12:11268. [PMID: 35787661 DOI: 10.1038/s41598-022-15209-3] [Reference Citation Analysis]
16 Wang X, Zhao C, Huang D, Liu Z, Liu M, Lin F, Lu Y, Jia J, Lin L, Lin X, Li H, Chen Z. A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma. Front Immunol 2022;13:923533. [DOI: 10.3389/fimmu.2022.923533] [Reference Citation Analysis]
17 Wang J, Huang F, Zhao J, Huang P, Tan J, Huang M, Ma R, Xiao Y, He S, Wang Z, Shen J, Lu H, Meng L. Tumor-Infiltrated CD8+ T Cell 10-Gene Signature Related to Clear Cell Renal Cell Carcinoma Prognosis. Front Immunol 2022;13:930921. [DOI: 10.3389/fimmu.2022.930921] [Reference Citation Analysis]
18 Wang S, Zhang S, Lin Z, Ma J, Zhu L, Liao G. Identification and Validation of an Apoptosis-Related Gene Prognostic Signature for Oral Squamous Cell Carcinoma. Front Oncol 2022;12:889049. [DOI: 10.3389/fonc.2022.889049] [Reference Citation Analysis]
19 Pei L, Zhang Y, Li G, Sun J. Comprehensive Analysis of the Expression and Prognosis for MCM4 in Uterine Corpus Endometrial Carcinoma. Front Genet 2022;13:890591. [DOI: 10.3389/fgene.2022.890591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhang Z, Chang WY, Wang K, Yang Y, Wang X, Yao C, Wu T, Wang L, Wang T. Interpreting the B-cell receptor repertoire with single-cell gene expression using Benisse. Nat Mach Intell. [DOI: 10.1038/s42256-022-00492-6] [Reference Citation Analysis]
21 Wang X, Lei W, Liu C, Yang J, Zhu Y. BOLA3 is a prognostic-related biomarker and correlated with immune infiltrates in lung adenocarcinoma. International Immunopharmacology 2022;107:108652. [DOI: 10.1016/j.intimp.2022.108652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
22 Kim S, Khadka D, Seo JH. Interplay between Solid Tumors and Tumor Microenvironment. Front Immunol 2022;13:882718. [DOI: 10.3389/fimmu.2022.882718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 He Z, Liu H, Guan H, Ji J, Jiang Y, Zhang N, Song Z, Wang X, Shen P, Wang H, Cui R. Construction of a Prognostic Model for Hypoxia-Related LncRNAs and Prediction of the Immune Landscape in the Digestive System Pan-Cancer. Front Oncol 2022;12:812786. [PMID: 35574385 DOI: 10.3389/fonc.2022.812786] [Reference Citation Analysis]
24 DeLucia DC, Lee JK. Development of Cancer Immunotherapies. Cancer Treat Res 2022;183:1-48. [PMID: 35551655 DOI: 10.1007/978-3-030-96376-7_1] [Reference Citation Analysis]
25 Wang L, Zhou S, Zhou Y, Lu J, Wang F. A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma. Journal of Immunology Research 2022;2022:1-18. [DOI: 10.1155/2022/8069858] [Reference Citation Analysis]
26 Sun S, Wang Y, Li M, Wu J. Identification of TRP-Related Subtypes, Development of a Prognostic Model, and Characterization of Tumor Microenvironment Infiltration in Lung Adenocarcinoma. Front Mol Biosci 2022;9:861380. [DOI: 10.3389/fmolb.2022.861380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ou H, Wei Y, Liu Y, Zhou F, Zhou Y. Characterization of the immune cell infiltration landscape in lung adenocarcinoma. Archives of Biochemistry and Biophysics 2022;721:109168. [DOI: 10.1016/j.abb.2022.109168] [Reference Citation Analysis]
28 Wang X, Jiang Z, Xu C, Meng W, Liu P, Zhang Y, Xie C, Xu J, Xie Y, Liang T, Yan H, Fan X, Yao X, Wu Q, Leung EL. Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response. Pharmacological Research 2022;179:106198. [DOI: 10.1016/j.phrs.2022.106198] [Reference Citation Analysis]
29 Xiao X, Shan H, Niu Y, Wang P, Li D, Zhang Y, Wang J, Wu Y, Jiang H. TMPRSS2 Serves as a Prognostic Biomarker and Correlated With Immune Infiltrates in Breast Invasive Cancer and Lung Adenocarcinoma. Front Mol Biosci 2022;9:647826. [DOI: 10.3389/fmolb.2022.647826] [Reference Citation Analysis]
30 Zheng P, Zhang H, Jiang W, Wang L, Liu L, Zhou Y, Zhou L, Liu H. Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity. Front Mol Biosci 2022;9:807497. [DOI: 10.3389/fmolb.2022.807497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Liu D, Heij LR, Czigany Z, Dahl E, Lang SA, Ulmer TF, Luedde T, Neumann UP, Bednarsch J. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma. J Exp Clin Cancer Res 2022;41:127. [PMID: 35392957 DOI: 10.1186/s13046-022-02340-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Barth DA, Stanzer S, Spiegelberg JA, Bauernhofer T, Absenger G, Szkandera J, Gerger A, Smolle MA, Hutterer GC, Ahyai SA, Madl T, Posch F, Riedl JM, Klec C, Jost PJ, Kargl J, Stradner MH, Pichler M. Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study. Front Immunol 2022;13:840207. [DOI: 10.3389/fimmu.2022.840207] [Reference Citation Analysis]
33 Lei R, Zhou M, Zhang S, Luo J, Qu C, Wang Y, Guo P, Huang R. Potential role of PRKCSH in lung cancer: bioinformatics analysis and a case study of Nano ZnO. Nanoscale 2022;14:4495-510. [PMID: 35254362 DOI: 10.1039/d1nr08133k] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Guan L, Zhang Z, Gao T, Fu S, Mu W, Liang S, Liu Y, Chu Q, Fang Y, Liu Y, Zhang N. Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage. ACS Nano 2022;16:4263-77. [PMID: 35179349 DOI: 10.1021/acsnano.1c10283] [Reference Citation Analysis]
35 Nai A, Ma F, He Z, Zeng S, Bashir S, Song J, Xu M. Development and Validation of a 7-Gene Inflammatory Signature Forecasts Prognosis and Diverse Immune Landscape in Lung Adenocarcinoma. Front Mol Biosci 2022;9:822739. [DOI: 10.3389/fmolb.2022.822739] [Reference Citation Analysis]
36 Wang J, Chi S, Bhagyaveni MA. Characterization of the Immune Cell Infiltration Landscape and a New Prognostic Score in Glioblastoma. Journal of Healthcare Engineering 2022;2022:1-9. [DOI: 10.1155/2022/4326728] [Reference Citation Analysis]
37 Lu Z, Liu R, Wang Y, Jiao M, Li Z, Wang Z, Huang C, Shi G, Ke A, Wang L, Fu Y, Xia J, Wen H, Zhou J, Wang X, Ye D, Fan J, Chu Y, Cai J. Ten-eleven translocation-2 inactivation restrains IL-10-producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. Hepatology 2022. [PMID: 35243663 DOI: 10.1002/hep.32442] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Mao G, Shan C, Li W, Liang B, Ma L, Zhang S. High Expression of RRM1 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma. IJGM 2022;Volume 15:2607-20. [DOI: 10.2147/ijgm.s353362] [Reference Citation Analysis]
39 Wu Y, Luo J, Li H, Huang Y, Zhu Y, Chen Q. B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma. Ann Transl Med 2022;10:295. [PMID: 35434016 DOI: 10.21037/atm-22-493] [Reference Citation Analysis]
40 Bai Z, Zhou Y, Ye Z, Xiong J, Lan H, Wang F. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. Front Immunol 2021;12:808964. [PMID: 35095898 DOI: 10.3389/fimmu.2021.808964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
41 Xiao L, Li Q, Huang Y, Fan Z, Ma L, Liu B, Yuan X, Srinivasan K. Construction of a Redox-Related Prognostic Model with Predictive Value in Survival and Therapeutic Response for Patients with Lung Adenocarcinoma. Journal of Healthcare Engineering 2022;2022:1-17. [DOI: 10.1155/2022/7651758] [Reference Citation Analysis]
42 Worsley CM, Veale RB, Mayne ES. The acidic tumour microenvironment: Manipulating the immune response to elicit escape. Hum Immunol 2022:S0198-8859(22)00030-1. [PMID: 35216847 DOI: 10.1016/j.humimm.2022.01.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Jiang J, Zhang F, Wan Y, Fang K, Yan ZD, Ren XL, Zhang R. Semaphorins as Potential Immune Therapeutic Targets for Cancer. Front Oncol 2022;12:793805. [PMID: 35155237 DOI: 10.3389/fonc.2022.793805] [Reference Citation Analysis]
44 Shi M, Mu Y, Shen N, Yuan Q. Integrated Analysis of miR-7-5p-Related ceRNA Network Reveals Potential Biomarkers for the Clinical Outcome of Gastric Cancer. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/8204818] [Reference Citation Analysis]
45 Zhao Z, Ju Q, Ji J, Li Y, Zhao Y. N6-Methyladenosine Methylation Regulator RBM15 is a Potential Prognostic Biomarker and Promotes Cell Proliferation in Pancreatic Adenocarcinoma. Front Mol Biosci 2022;9:842833. [DOI: 10.3389/fmolb.2022.842833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
46 Li JH, O'Sullivan TE. Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function. Front Immunol 2021;12:816658. [PMID: 35082797 DOI: 10.3389/fimmu.2021.816658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Hu K, Yao L, Xu Z, Yan Y, Li J. Prognostic Value and Therapeutic Potential of CBX Family Members in Ovarian Cancer. Front Cell Dev Biol 2022;10:832354. [DOI: 10.3389/fcell.2022.832354] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Berk Ş, Kaya S, Akkol EK, Bardakçı H. A comprehensive and current review on the role of flavonoids in lung cancer-Experimental and theoretical approaches. Phytomedicine 2022;98:153938. [PMID: 35123170 DOI: 10.1016/j.phymed.2022.153938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Wang Z, Liu Y, Peng L, Till B, Liao Y, Yuan S, Yan X, Chen L, Fu Q, Qin Z. Role of fibrosarcoma-induced CD11b+ myeloid cells and tumor necrosis factor-α in B cell responses. Oncogene 2022. [PMID: 35034094 DOI: 10.1038/s41388-022-02187-z] [Reference Citation Analysis]
50 Leng Y, Dang S, Yin F, Gao T, Xiao X, Zhang Y, Chen L, Qin C, Lai N, Zhan XY, Huang K, Luo C, Kang Y, Wang N, Li Y, Liang Y, Huang B. GDPLichi: a DNA Damage Repair-Related Gene Classifier for Predicting Lung Adenocarcinoma Immune Checkpoint Inhibitors Response. Front Oncol 2021;11:733533. [PMID: 34970479 DOI: 10.3389/fonc.2021.733533] [Reference Citation Analysis]
51 Huang J, Xie Z; Clinical Laboratory Center, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China, Geriatrics Department, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China. . MBE 2022;19:3022-35. [DOI: 10.3934/mbe.2022139] [Reference Citation Analysis]
52 He W, Wang B, He J, Zhao Y, Zhao W. SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma. Expert Rev Mol Diagn 2021;:1-9. [PMID: 34904499 DOI: 10.1080/14737159.2022.2019015] [Reference Citation Analysis]
53 Lu G, Shi W, Zhang Y. Prognostic Implications and Immune Infiltration Analysis of ALDOA in Lung Adenocarcinoma. Front Genet 2021;12:721021. [PMID: 34925439 DOI: 10.3389/fgene.2021.721021] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
54 Xia L, Guo L, Kang J, Yang Y, Yao Y, Xia W, Sun R, Zhang S, Li W, Gao Y, Chen H, Li Z, Yang J, Lu S, Wang Y. Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer. Front Immunol 2021;12:759217. [PMID: 34899709 DOI: 10.3389/fimmu.2021.759217] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Qiu BQ, Lin XH, Lai SQ, Lu F, Lin K, Long X, Zhu SQ, Zou HX, Xu JJ, Liu JC, Wu YB. ITGB1-DT/ARNTL2 axis may be a novel biomarker in lung adenocarcinoma: a bioinformatics analysis and experimental validation. Cancer Cell Int 2021;21:665. [PMID: 34906142 DOI: 10.1186/s12935-021-02380-2] [Reference Citation Analysis]
56 Vaes RDW, Reynders K, Sprooten J, Nevola KT, Rouschop KMA, Vooijs M, Garg AD, Lambrecht M, Hendriks LEL, Rucevic M, De Ruysscher D. Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study. Cancers (Basel) 2021;13:6259. [PMID: 34944879 DOI: 10.3390/cancers13246259] [Reference Citation Analysis]
57 Li N, Wang J, Zhan X. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. Front Immunol 2021;12:752643. [PMID: 34887858 DOI: 10.3389/fimmu.2021.752643] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
58 Xie F, Dong H, Zhang H. Regulatory Functions of Protein Tyrosine Phosphatase Receptor Type O in Immune Cells. Front Immunol 2021;12:783370. [PMID: 34880876 DOI: 10.3389/fimmu.2021.783370] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Zeng R, Huang S, Qiu X, Zhuo Z, Wu H, Jiang L, Sha W, Chen H. Predicting the Prognosis of Esophageal Adenocarcinoma by a Pyroptosis-Related Gene Signature. Front Pharmacol 2021;12:767187. [PMID: 34867395 DOI: 10.3389/fphar.2021.767187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Huang T, Ye W, Lin X. Alternative Splicing Events in Immune Infiltration of Lung Adenocarcinoma. Med Sci Monit 2021;27:e934491. [PMID: 34864813 DOI: 10.12659/MSM.934491] [Reference Citation Analysis]
61 Pan J, Yang H, Zhu L, Lou Y. Correlation of ARNTL2 with Immune Infiltration and Its Role as a Potential Prognostic Biomarker in Lung Adenocarcinoma. Clinical Complementary Medicine and Pharmacology 2021;1:100005. [DOI: 10.1016/j.ccmp.2021.100005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Liang ZQ, Gao L, Chen JH, Dai WB, Su YS, Chen G. Downregulation of the Coiled-Coil Domain Containing 80 and Its Perspective Mechanisms in Ovarian Carcinoma: A Comprehensive Study. Int J Genomics 2021;2021:3752871. [PMID: 34820451 DOI: 10.1155/2021/3752871] [Reference Citation Analysis]
63 Pan J, Ye F, Yu C, Zhu Q, Li J, Zhang Y, Tian H, Yao Y, Zhu M, Shen Y, Zhu F, Wang Y, Zhou X, Guo G, Wu Y. Papillary Thyroid Carcinoma Landscape and Its Immunological Link With Hashimoto Thyroiditis at Single-Cell Resolution. Front Cell Dev Biol 2021;9:758339. [PMID: 34805166 DOI: 10.3389/fcell.2021.758339] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
64 Gao SH, Liu SZ, Wang GZ, Zhou GB. CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities. Life (Basel) 2021;11:1282. [PMID: 34947813 DOI: 10.3390/life11121282] [Reference Citation Analysis]
65 Zhou H, Bian T, Qian L, Zhao C, Zhang W, Zheng M, Zhou H, Liu L, Sun H, Li X, Zhang J, Liu Y. Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration. Pathol Res Pract 2021;228:153680. [PMID: 34798483 DOI: 10.1016/j.prp.2021.153680] [Reference Citation Analysis]
66 Kim EY, Cha YJ, Lee SH, Jeong S, Choi YJ, Moon DH, Lee S, Chang YS. Early lung carcinogenesis and tumor microenvironment observed by single-cell transcriptome analysis. Transl Oncol 2021;15:101277. [PMID: 34800916 DOI: 10.1016/j.tranon.2021.101277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
67 Zheng Q, Wang Z, Zhang M, Yu Y, Chen R, Lu T, Liu L, Ma J, Liu T, Zheng H, Li H, Li J. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation. BMC Cancer 2021;21:1216. [PMID: 34774014 DOI: 10.1186/s12885-021-08957-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
68 Li X, Yao Y, Qian J, Jin G, Zeng G, Zhao H. Overexpression and diagnostic significance of INTS7 in lung adenocarcinoma and its effects on tumor microenvironment. Int Immunopharmacol 2021;101:108346. [PMID: 34781123 DOI: 10.1016/j.intimp.2021.108346] [Reference Citation Analysis]
69 Zhang H, Ju Q, Ji J, Zhao Y. Pan-Cancer Analysis Reveals FH as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma. Dis Markers 2021;2021:8554844. [PMID: 34737838 DOI: 10.1155/2021/8554844] [Reference Citation Analysis]
70 Wang Z, Zhang M, Wu Y, Yu Y, Zheng Q, Li J. CKS2 Overexpression Correlates with Prognosis and Immune Cell Infiltration in Lung Adenocarcinoma: A Comprehensive Study based on Bioinformatics and Experiments. J Cancer 2021;12:6964-78. [PMID: 34729099 DOI: 10.7150/jca.63625] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
71 Qin M, Jin Y, Pan LY. Tertiary lymphoid structure and B-cell-related pathways: A potential target in tumor immunotherapy. Oncol Lett 2021;22:836. [PMID: 34712360 DOI: 10.3892/ol.2021.13097] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
72 Sun Y, Li W, Li X, Zheng H, Qiu Y, Yang H. Oncogenic role of karyopherin α2 (KPNA2) in human tumors: A pan-cancer analysis. Comput Biol Med 2021;139:104955. [PMID: 34735944 DOI: 10.1016/j.compbiomed.2021.104955] [Reference Citation Analysis]
73 Zhong S, Huang C, Chen Z, Chen Z, Luo JL. Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance. J Clin Med 2021;10:5000. [PMID: 34768524 DOI: 10.3390/jcm10215000] [Reference Citation Analysis]
74 Zhang XQ, Li L. Biological Function and Clinical Value of VPS13A in Pan-Cancer Based on Bioinformatics Analysis. Int J Gen Med 2021;14:6825-38. [PMID: 34690502 DOI: 10.2147/IJGM.S330256] [Reference Citation Analysis]
75 Zhao C, Chen J, Liu Y, Ju S, Wang G, Wang X. Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer. Bioengineered 2021. [PMID: 34699318 DOI: 10.1080/21655979.2021.1996513] [Reference Citation Analysis]
76 Caruntu A, Moraru L, Surcel M, Munteanu A, Tanase C, Constantin C, Zurac S, Caruntu C, Neagu M. Assessment of Immune Cell Populations in Tumor Tissue and Peripheral Blood Samples from Head and Neck Squamous Cell Carcinoma Patients. Anal Cell Pathol (Amst) 2021;2021:2328218. [PMID: 34692375 DOI: 10.1155/2021/2328218] [Reference Citation Analysis]
77 Liang ZQ, Zhong LY, Li J, Shen JH, Tu XY, Zhong ZH, Zeng JJ, Chen JH, Wei ZX, Dang YW, Huang SN, Chen G. Clinicopathological significance and underlying molecular mechanism of downregulation of basonuclin 1 expression in ovarian carcinoma. Exp Biol Med (Maywood) 2021;:15353702211052036. [PMID: 34644201 DOI: 10.1177/15353702211052036] [Reference Citation Analysis]
78 Qi J, Liu X, Yan P, He S, Lin Y, Huang Z, Zhang S, Xie S, Li Y, Lu X, Wu Y, Zhou Y, Yuan J, Cai T, Zheng X, Ding Y, Yang W. Analysis of Immune Landscape Reveals Prognostic Significance of Cytotoxic CD4+ T Cells in the Central Region of pMMR CRC. Front Oncol 2021;11:724232. [PMID: 34631551 DOI: 10.3389/fonc.2021.724232] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Zhang Y, Yin X, Wang Q, Song X, Xia W, Mao Q, Chen B, Liang Y, Zhang T, Xu L, Jiang F, Xu X, Dong G. A novel gene expression signature-based on B-cell proportion to predict prognosis of patients with lung adenocarcinoma. BMC Cancer 2021;21:1098. [PMID: 34641822 DOI: 10.1186/s12885-021-08805-5] [Reference Citation Analysis]
80 Ye G, Liu Y, Huang L, Zhang C, Sheng Y, Wu B, Wu C, Qi Y. miRNA-218/FANCI is associated with metastasis and poor prognosis in lung adenocarcinoma: a bioinformatics analysis. Ann Transl Med 2021;9:1298. [PMID: 34532435 DOI: 10.21037/atm-21-3823] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Wang J, Luo FF, Huang TJ, Mei Y, Peng LX, Qian CN, Huang BJ. The upregulated expression of RFC4 and GMPS mediated by DNA copy number alteration is associated with the early diagnosis and immune escape of ESCC based on a bioinformatic analysis. Aging (Albany NY) 2021;13:21758-77. [PMID: 34520390 DOI: 10.18632/aging.203520] [Reference Citation Analysis]
82 Jia L, Wang T, Zhao Y, Zhang S, Ba T, Kuai X, Wang B, Zhang N, Zhao W, Yang Z, Qiao H. Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas. Oncoimmunology 2021;10:1969767. [PMID: 34513317 DOI: 10.1080/2162402X.2021.1969767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 He K, Barsoumian HB, Sezen D, Puebla-Osorio N, Hsu EY, Verma V, Abana CO, Chen D, Patel RR, Gu M, Cortez MA, Welsh JW. Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. Front Oncol 2021;11:737425. [PMID: 34497773 DOI: 10.3389/fonc.2021.737425] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Gu Y, Tang S, Wang Z, Cai L, Lian H, Shen Y, Zhou Y. A pan-cancer analysis of the prognostic and immunological role of β-actin (ACTB) in human cancers. Bioengineered 2021;12:6166-85. [PMID: 34486492 DOI: 10.1080/21655979.2021.1973220] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Ma W, Zeng J, Chen S, Lyu Y, Toomey KA, Phan CT, Yoneda KY, Li T. Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC. Biomark Res 2021;9:69. [PMID: 34488906 DOI: 10.1186/s40364-021-00324-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
86 Jiang H, Chen H, Wan P, Chen N. Decreased expression of HADH is related to poor prognosis and immune infiltration in kidney renal clear cell carcinoma. Genomics 2021;113:3556-64. [PMID: 34391866 DOI: 10.1016/j.ygeno.2021.08.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Zhu Y, Pu Z, Li Z, Lin Y, Li N, Peng F. Comprehensive Analysis of the Expression and Prognosis Value of Chromobox Family Members in Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:700528. [PMID: 34395271 DOI: 10.3389/fonc.2021.700528] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
88 Aizik L, Dror Y, Taussig D, Barzel A, Carmi Y, Wine Y. Antibody Repertoire Analysis of Tumor-Infiltrating B Cells Reveals Distinct Signatures and Distributions Across Tissues. Front Immunol 2021;12:705381. [PMID: 34349765 DOI: 10.3389/fimmu.2021.705381] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
89 Lv L, Zhang Y, Zhao Y, Wei Q, Zhao Y, Yi Q. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma. Front Cell Neurosci 2021;15:704344. [PMID: 34335194 DOI: 10.3389/fncel.2021.704344] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
90 Ramachandran S, Verma AK, Dev K, Goyal Y, Bhatt D, Alsahli MA, Rahmani AH, Almatroudi A, Almatroodi SA, Alrumaihi F, Khan NA. Role of Cytokines and Chemokines in NSCLC Immune Navigation and Proliferation. Oxid Med Cell Longev 2021;2021:5563746. [PMID: 34336101 DOI: 10.1155/2021/5563746] [Reference Citation Analysis]
91 Li JP, Wu CY, Chen MY, Liu SX, Yan SM, Kang YF, Sun C, Grandis JR, Zeng MS, Zhong Q. PD-1+CXCR5-CD4+ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. J Immunother Cancer 2021;9:e002101. [PMID: 34253636 DOI: 10.1136/jitc-2020-002101] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
92 Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021;6:263. [PMID: 34248142 DOI: 10.1038/s41392-021-00658-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 114] [Article Influence: 1.0] [Reference Citation Analysis]
93 Jiang F, Liang M, Huang X, Shi W, Wang Y. High expression of PIMREG predicts poor survival outcomes and is correlated with immune infiltrates in lung adenocarcinoma. PeerJ 2021;9:e11697. [PMID: 34268011 DOI: 10.7717/peerj.11697] [Reference Citation Analysis]
94 Wei Y, Huang CX, Xiao X, Chen DP, Shan H, He H, Kuang DM. B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments. Oncogene 2021;40:4737-45. [PMID: 34188249 DOI: 10.1038/s41388-021-01918-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
95 Pylaeva E, Ozel I, Squire A, Spyra I, Wallner C, Korek M, Korschunow G, Domnich M, Siakaeva E, Goetz M, Bankfalvi A, Lang S, Kansy B, Jablonska J. B-Helper Neutrophils in Regional Lymph Nodes Correlate with Improved Prognosis in Patients with Head and Neck Cancer. Cancers (Basel) 2021;13:3092. [PMID: 34205654 DOI: 10.3390/cancers13123092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
96 Li X, Han QC, Yu C, Luo YC, Wang F, Sun XH, Gao YQ, Tan WF, Xia Q. C-C chemokine hepatocellular carcinoma motif ligand 5-deficiency promotes hepatocellular carcinoma progression by affecting B cell recruitment. J Dig Dis 2021;22:433-41. [PMID: 33978316 DOI: 10.1111/1751-2980.12997] [Reference Citation Analysis]
97 Liu QF, Feng ZY, Jiang LL, Xu TT, Li SM, Liu KR. Immune Cell Infiltration as Signatures for the Diagnosis and Prognosis of Malignant Gynecological Tumors. Front Cell Dev Biol 2021;9:702451. [PMID: 34222265 DOI: 10.3389/fcell.2021.702451] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
98 Jiang ZB, Wang WJ, Xu C, Xie YJ, Wang XR, Zhang YZ, Huang JM, Huang M, Xie C, Liu P, Fan XX, Ma YP, Yan PY, Liu L, Yao XJ, Wu QB, Lai-Han Leung E. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett 2021;515:36-48. [PMID: 34052328 DOI: 10.1016/j.canlet.2021.05.019] [Reference Citation Analysis]
99 Huo G, Wang Y, Chen J, Song Y, Zhang C, Guo H, Zuo R, Zhu F, Cui J, Chen W, Chen W, Chen P. A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors. Front Oncol 2021;11:692136. [PMID: 34113576 DOI: 10.3389/fonc.2021.692136] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
100 Chen Z, Zhang L, Yang J, Zheng L, Hu F, Duan S, Nandakumar KS, Liu S, Yin H, Cheng K. Design, Synthesis, and Structure-Activity Relationship of N-Aryl-N'-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy. J Med Chem 2021;64:7371-89. [PMID: 34029463 DOI: 10.1021/acs.jmedchem.0c02266] [Reference Citation Analysis]
101 Peng L, Zhang Y, Wang Z. Immune Responses against Disseminated Tumor Cells. Cancers (Basel) 2021;13:2515. [PMID: 34063848 DOI: 10.3390/cancers13112515] [Reference Citation Analysis]
102 Huber RM, Kauffmann-Guerrero D, Hoffmann H, Flentje M. New developments in locally advanced nonsmall cell lung cancer. Eur Respir Rev 2021;30:200227. [PMID: 33952600 DOI: 10.1183/16000617.0227-2020] [Reference Citation Analysis]
103 Ren S, Wang W, Zhang C, Sun Y, Sun M, Wang Y, Zhang X, Lu B, Yao L. The low expression of NUP62CL indicates good prognosis and high level of immune infiltration in lung adenocarcinoma. Cancer Med 2021;10:3403-12. [PMID: 33934535 DOI: 10.1002/cam4.3877] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer 2021;21:360-78. [PMID: 33907315 DOI: 10.1038/s41568-021-00346-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 142] [Article Influence: 15.0] [Reference Citation Analysis]
105 Lan T, Liu W, Lu Y, Luo H. A five-gene signature for predicting overall survival of esophagus adenocarcinoma. Medicine (Baltimore) 2021;100:e25305. [PMID: 33832101 DOI: 10.1097/MD.0000000000025305] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Hu Q, Hong Y, Qi P, Lu G, Mai X, Xu S, He X, Guo Y, Gao L, Jing Z, Wang J, Cai T, Zhang Y. Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nat Commun 2021;12:2186. [PMID: 33846305 DOI: 10.1038/s41467-021-22300-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
107 Jang JW, Thuy PX, Lee JW, Moon EY. CXCR4 promotes B cell viability by the cooperation of nuclear factor (erythroid-derived 2)-like 2 and hypoxia-inducible factor-1α under hypoxic conditions. Cell Death Dis 2021;12:330. [PMID: 33771976 DOI: 10.1038/s41419-021-03615-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
108 Zhao Y, Chen C, Xu X, Ge X, Ding K, Zheng S, Wang J, Sun L. An Efficient Prognostic Immune Scoring System For Colorectal Cancer Patients With Peritoneal Metastasis. Oncoimmunology 2021;10:1901464. [PMID: 33796414 DOI: 10.1080/2162402X.2021.1901464] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Jang JW, Park S, Moon EY. Spleen tyrosine kinase regulates crosstalk of hypoxia-inducible factor-1α and nuclear factor (erythroid-derived2)-like 2 for B cell survival. Int Immunopharmacol 2021;95:107509. [PMID: 33761438 DOI: 10.1016/j.intimp.2021.107509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Zhang C, Wang L, Liu H, Deng G, Xu P, Tan Y, Xu Y, Liu B, Chen Q, Tian D. ADPRH is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma. J Cancer 2021;12:2912-20. [PMID: 33854592 DOI: 10.7150/jca.51643] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Diao JA, Wang JK, Chui WF, Mountain V, Gullapally SC, Srinivasan R, Mitchell RN, Glass B, Hoffman S, Rao SK, Maheshwari C, Lahiri A, Prakash A, McLoughlin R, Kerner JK, Resnick MB, Montalto MC, Khosla A, Wapinski IN, Beck AH, Elliott HL, Taylor-Weiner A. Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes. Nat Commun 2021;12:1613. [PMID: 33712588 DOI: 10.1038/s41467-021-21896-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
112 Arora L, Pal D. Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression. Front Oncol 2021;11:596798. [PMID: 33763348 DOI: 10.3389/fonc.2021.596798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
113 Ye X, Wei J, Yue M, Wang Y, Chen H, Zhang Y, Wang Y, Zhang M, Huang P, Yu R. Leveraging Single-Cell RNA-seq Data to Uncover the Association Between Cell Type and Chronic Liver Diseases. Front Genet 2021;12:637322. [PMID: 33763117 DOI: 10.3389/fgene.2021.637322] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Su D, Wu G, Xiong R, Sun X, Xu M, Mei Y, Wu X. Tumor Immune Microenvironment Characteristics and Their Prognostic Value in Non-Small-Cell Lung Cancer. Front Oncol 2021;11:634059. [PMID: 33747957 DOI: 10.3389/fonc.2021.634059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
115 Suárez-Sánchez FJ, Lequerica-Fernández P, Rodrigo JP, Hermida-Prado F, Suárez-Canto J, Rodríguez-Santamarta T, Domínguez-Iglesias F, García-Pedrero JM, de Vicente JC. Tumor-Infiltrating CD20+ B Lymphocytes: Significance and Prognostic Implications in Oral Cancer Microenvironment. Cancers (Basel) 2021;13:395. [PMID: 33494389 DOI: 10.3390/cancers13030395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Zhao Y, Zhang M, Pu H, Guo S, Zhang S, Wang Y. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment. Front Oncol 2020;10:585961. [PMID: 33552963 DOI: 10.3389/fonc.2020.585961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
117 Wang X, Asami S, Kitamura D. A novel cancer immunotherapy using tumor-infiltrating B cells in the APCmin/+ mouse model. PLoS One 2021;16:e0245608. [PMID: 33465122 DOI: 10.1371/journal.pone.0245608] [Reference Citation Analysis]
118 Chen J, Zhou R. Tumor microenvironment related novel signature predict lung adenocarcinoma survival. PeerJ 2021;9:e10628. [PMID: 33520448 DOI: 10.7717/peerj.10628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
119 Miao H, Chen D, Li R, Hu J, Chen Y, Xu C, Wen Z. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung. Biosci Rep 2021;41:BSR20202444. [PMID: 33324975 DOI: 10.1042/BSR20202444] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
120 Pradhan M, Chocry M, Gibbons DL, Sepesi B, Cascone T. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Transl Lung Cancer Res 2021;10:590-606. [PMID: 33569339 DOI: 10.21037/tlcr-20-573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
121 Liu Y, Xie P, Jiang D, Liu J, Zhang J, Bian T, Shi J. Molecular and Immune Characteristics for Lung Adenocarcinoma Patients With ERLIN2 Overexpression. Front Immunol 2020;11:568440. [PMID: 33424830 DOI: 10.3389/fimmu.2020.568440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Zhou H, He Y, Li L, Wu C, Hu G. Overexpression of P4HA1 Is Correlated with Poor Survival and Immune Infiltrates in Lung Adenocarcinoma. Biomed Res Int 2020;2020:8024138. [PMID: 33299876 DOI: 10.1155/2020/8024138] [Reference Citation Analysis]
123 Lian J, Yue Y, Yu W, Zhang Y. Immunosenescence: a key player in cancer development. J Hematol Oncol 2020;13:151. [PMID: 33168037 DOI: 10.1186/s13045-020-00986-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 52] [Article Influence: 5.5] [Reference Citation Analysis]
124 Zhang Y, Liu Q, Liao Q. Long noncoding RNA: a dazzling dancer in tumor immune microenvironment. J Exp Clin Cancer Res 2020;39:231. [PMID: 33148302 DOI: 10.1186/s13046-020-01727-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
125 Han L, Shi H, Luo Y, Sun W, Li S, Zhang N, Jiang X, Gong Y, Xie C. Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma. Cancer Med 2020;9:9581-94. [PMID: 33098370 DOI: 10.1002/cam4.3561] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
126 Liu J, Han X, Chen L, Han D, Mu X, Hu X, Wu H, Wu H, Liu W, Zhao Y. TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma. Aging (Albany NY) 2020;12:20308-31. [PMID: 33091876 DOI: 10.18632/aging.103804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
127 Ma C, Luo H, Cao J, Zheng X, Zhang J, Zhang Y, Fu Z. Identification of a Novel Tumor Microenvironment-Associated Eight-Gene Signature for Prognosis Prediction in Lung Adenocarcinoma. Front Mol Biosci 2020;7:571641. [PMID: 33102522 DOI: 10.3389/fmolb.2020.571641] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
128 Zeng QH, Wei Y, Lao XM, Chen DP, Huang CX, Lin QY, He M, Liao Y, Zheng L, Li B, Zhang GB, Chen Y, Kuang DM. B cells polarize pathogenic inflammatory T helper subsets through ICOSL-dependent glycolysis. Sci Adv 2020;6:eabb6296. [PMID: 32917682 DOI: 10.1126/sciadv.abb6296] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
129 Wang L, Jiang P, Zhao S, Liu H, Liu L, Mor G, Liu C, Liao A. The dynamic profile and potential function of B-cell subsets during pregnancy. Cell Mol Immunol 2021;18:1082-4. [PMID: 32879470 DOI: 10.1038/s41423-020-00535-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
130 Kang Y, Datta P, Shanmughapriya S, Ozbolat IT. 3D Bioprinting of Tumor Models for Cancer Research. ACS Appl Bio Mater 2020;3:5552-73. [DOI: 10.1021/acsabm.0c00791] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
131 van de Veen W, Globinska A, Jansen K, Straumann A, Kubo T, Verschoor D, Wirz OF, Castro-Giner F, Tan G, Rückert B, Ochsner U, Herrmann M, Stanić B, van Splunter M, Huntjens D, Wallimann A, Fonseca Guevara RJ, Spits H, Ignatova D, Chang YT, Fassnacht C, Guenova E, Flatz L, Akdis CA, Akdis M. A novel proangiogenic B cell subset is increased in cancer and chronic inflammation. Sci Adv 2020;6:eaaz3559. [PMID: 32426497 DOI: 10.1126/sciadv.aaz3559] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
132 Liang J, Chen D, Chen L, She X, Zhang H, Xiao Y. The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers. Future Oncol 2020;16:1211-23. [PMID: 32396026 DOI: 10.2217/fon-2020-0118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Zhou M, Zhang Z, Bao S, Hou P, Yan C, Su J, Sun J. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform 2021;22:bbaa047. [PMID: 32382761 DOI: 10.1093/bib/bbaa047] [Cited by in Crossref: 24] [Cited by in F6Publishing: 76] [Article Influence: 12.0] [Reference Citation Analysis]
134 Wang H, Gao J, Zhang R, Li M, Peng Z, Wang H. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression. Int Immunopharmacol 2020;83:106478. [PMID: 32278132 DOI: 10.1016/j.intimp.2020.106478] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
135 Coleman MF, Cozzo AJ, Pfeil AJ, Etigunta SK, Hursting SD. Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy. Cancers (Basel) 2020;12:E852. [PMID: 32244756 DOI: 10.3390/cancers12040852] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
136 Sun J, Xie T, Jamal M, Tu Z, Li X, Wu Y, Li J, Zhang Q, Huang X. CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment. Cancer Cell Int 2020;20:106. [PMID: 32265595 DOI: 10.1186/s12935-020-01183-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
137 Cen Y, Huang Z, Ren J, Zhang J, Gong Y, Xie C. The characteristic of tumor immune microenvironment in pulmonary carcinosarcoma. Immunotherapy 2020;12:323-31. [PMID: 32212951 DOI: 10.2217/imt-2019-0123] [Reference Citation Analysis]
138 Yuan K, Feng Y, Wang H, Zhao L, Wang W, Wang T, Feng Y, Huang G, Xu A. FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma. PeerJ 2020;8:e8654. [PMID: 32206449 DOI: 10.7717/peerj.8654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
139 Subramaniyan B, Rajaputra P, Nguyen L, Li M, Peer CJ, Kindrick J, Figg WD, Woo S, You Y. Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models. Photochem Photobiol 2020;96:668-79. [PMID: 31883393 DOI: 10.1111/php.13202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Li Y, Li CQ, Guo SJ, Guo W, Jiang HW, Li HC, Tao SC. Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma. EBioMedicine 2020;53:102674. [PMID: 32113159 DOI: 10.1016/j.ebiom.2020.102674] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
141 Patel AJ, Richter A, Drayson MT, Middleton GW. The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer. Cancer Immunol Immunother 2020;69:325-42. [PMID: 31901949 DOI: 10.1007/s00262-019-02461-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
142 Wang W, Ren S, Wang Z, Zhang C, Huang J. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level. Int Immunopharmacol 2020;78:106077. [PMID: 31812070 DOI: 10.1016/j.intimp.2019.106077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
143 Kamata T, Yoshida S, Takami M, Ihara F, Yoshizawa H, Toyoda T, Takeshita Y, Nobuyama S, Kanetsuna Y, Sato T, Yoshino I, Motohashi S. Immunological features of a lung cancer patient achieving an objective response with anti-programmed death-1 blockade therapy. Cancer Sci 2020;111:288-96. [PMID: 31677359 DOI: 10.1111/cas.14222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
144 Zhang L, Huang Y, Lindstrom AR, Lin TY, Lam KS, Li Y. Peptide-based materials for cancer immunotherapy. Theranostics 2019;9:7807-25. [PMID: 31695802 DOI: 10.7150/thno.37194] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
145 Riera-Domingo C, Audigé A, Granja S, Cheng WC, Ho PC, Baltazar F, Stockmann C, Mazzone M. Immunity, Hypoxia, and Metabolism-the Ménage à Trois of Cancer: Implications for Immunotherapy. Physiol Rev 2020;100:1-102. [PMID: 31414610 DOI: 10.1152/physrev.00018.2019] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 16.0] [Reference Citation Analysis]
146 Xue W, Yan D, Kan Q. Interleukin-35 as an Emerging Player in Tumor Microenvironment. J Cancer 2019;10:2074-82. [PMID: 31205568 DOI: 10.7150/jca.29170] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
147 Yang JG, Wang WM, Xia HF, Yu ZL, Li HM, Ren JG, Chen G, Wang BK, Jia J, Zhang W, Zhao YF. Lymphotoxin-α promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3-dependent manner. Int J Cancer 2019;145:1358-70. [PMID: 30785217 DOI: 10.1002/ijc.32221] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
148 Li Y, Zhao C, Liu J, Lu Z, Lu M, Gu J, Liu R. CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity. Oncol Rep 2019;41:2679-88. [PMID: 30864713 DOI: 10.3892/or.2019.7037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
149 Hadler-Olsen E, Wirsing AM. Tissue-infiltrating immune cells as prognostic markers in oral squamous cell carcinoma: a systematic review and meta-analysis. Br J Cancer 2019;120:714-27. [PMID: 30808992 DOI: 10.1038/s41416-019-0409-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
150 Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W, Baba H, Lenz HJ. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev 2019;73:10-9. [PMID: 30551036 DOI: 10.1016/j.ctrv.2018.12.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
151 Liu J, Li Y, Lu Z, Gu J, Liang Y, Huang E, Wang Z, Zhang H, Wang L, Zhang D, Yu H, Liu R, Chu Y. Deceleration of glycometabolism impedes IgG-producing B-cell-mediated tumor elimination by targeting SATB1. Immunology 2019;156:56-68. [PMID: 30171602 DOI: 10.1111/imm.12998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
152 Seo JS, Kim A, Shin JY, Kim YT. Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor. Sci Rep 2018;8:14576. [PMID: 30275546 DOI: 10.1038/s41598-018-32855-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]